CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Bayer to buy Perfuse Therapeutics for $300M upfront

Positive
AI Analysis

Summary

Bayer is acquiring ophthalmology biotech Perfuse Therapeutics for $300 million upfront to gain access to mid-stage programs targeting blindness.

Importance:7/10
Sentiment:
0.60
M&Aophthalmologyacquisitionmid-stage
Related Companies

Read the original article

Published by Endpoints News on May 6, 2026 10:56 AM

Read Original